Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

The PE time bomb — Provident’s Abe M’Bodj on where investment in GI is headed in 2019

Provident Healthcare Partners
Skip to the end of the Expertise Menu

The PE time bomb — Provident’s Abe M’Bodj on where investment in GI is headed in 2019

While three private equity firms have invested in gastroenterology to date, several analysts believe more deals are on the way in 2019.

Here, Provident Healthcare Partners Associate Abe M’Bodj analyzed the current state of the market and offered insights into what the rest of the year could look like as well as how all PE firms can coexist.

Question: Several analysts believed the beginning of 2019 would further ramp up PE investment in GI firms. Why haven’t there been any deals closing in 2019?

Abe M’Bodj: While the activity did ramp up at the end of 2018, the [Southlake-based] Texas Digestive Disease Consultants and Atlanta Gastroenterology Associates deals were transaction processes that were ongoing for a fairly significant amount of time.

As you might imagine, these transactions are complex and on average take about nine months to a year or more to complete. The vast majority of GI practices that are currently exploring the market had their interest sparked by the TDDC and AGA transactions. With those transactions just complete, we expect to see a much larger pickup in activity during the latter half of 2019 and in the beginning half of 2020.

Click the following link to access the full article: The PE time bomb — Provident’s Abe M’Bodj on where investment in GI is headed in 2019

About Becker’s ASC Review
Becker’s ASC Review features general business, legal and clinical guidance on topics relevant to outpatient surgery including joint-ventures, development and expansion, and regulatory and compliance issues; as well as analysis and insight for specialties including bariatrics, orthopedics and spine, gastroenterology, neurosurgery, ophthalmology, ENT and anesthesiology. Each of the nine annual issues of the publication reaches a qualified audience of more than 25,000 key ASC leaders, including surgeons, medical directors, directors of surgery and ASC administrators. Further, every ASC in the nation receives Becker’s ASC Review. Visit Becker’s ASC Review at https://www.beckersasc.com/.